REDWOOD CITY, Calif. & ORLANDO, Fla.--(BUSINESS WIRE)--A.P. Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, today announced additional findings from the Company’s Phase 3 study of APF530 for the prevention of chemotherapy-induced nausea and vomiting (CINV). The new data were included in a poster presentation during the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO). APF530 is a long-acting formulation of granisetron that utilizes the Company’s proprietary Biochronomer™ drug delivery system. The Company filed a new drug application (NDA) for APF530 in May 2009.
